Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities—a case report with literature reviewAnti-synthetase syndrome: 양측 유리막 혼탁에 대한 드물고 어려운 진단 - 문헌 검토가 포함된 증례 보고서Review Published on 2021-01-062022-09-01 Journal: BMC Pulmonary Medicine [Category] 진단, [키워드] Anti-synthetase syndrome antibodies Arthritis association Autoimmune Autoimmune disease Case report changes in characterized chest imaging Clinical improvement clinical suspicion Corticosteroid Corticosteroids COVID-19 pandemic Diagnosis disease early treatment feature Fever ILD Immune-mediated immunomodulator immunomodulators immunosuppressive agent Immunosuppressive agents IMPROVE Interstitial lung disease less literature review Lung disease myositis outcome Patient presenting prognostic respiratory respiratory symptom skin changes survival suspicion syndrome therapy [DOI] 10.1186/s12890-020-01388-0 PMC 바로가기 [Article Type] Review
Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in SwitzerlandPediatrics Published on 2021-01-052022-10-31 Journal: Frontiers in Pediatrics [Category] COVID-19, [키워드] addition Anakinra anti-IL6 Anti-inflammatory benefit case sery Child children clinical feature Cohort country cytokine profile Cytokine storm defined dose Evidence Evolution Hyperinflammatory IL-1 IL-1ra IL-6 IL-6 blocking Immunoglobulin immunomodulator Incomplete Inflammatory Intravenous immunoglobulin Laboratory medication MIS-C one patient overlap pandemic Patient presenting recent reported SARS-CoV-2 SARS-CoV2 Serum level Sery severe SARS-CoV-2 steroid steroid treatment Switzerland syndrome tested therapy toxic TSS [DOI] 10.3389/fped.2020.594127 PMC 바로가기 [Article Type] Pediatrics
Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, SpainObservational Study Published on 2021-01-012022-10-05 Journal: Inflammatory bowel diseases [Category] 임상, [키워드] 95% CI 95% confidence interval Analysis biologic clinical Clinical course Comorbidities COVID-19 Crohn disease cross-sectional diagnosed diarrhea died disease Dyspnea female greater IBD identify immunomodulator Immunosuppression incidence Infection Inflammatory bowel disease medical record Mild moderate MOST myalgia Odds ratio one patient Patient patient age patients reported SARS-CoV-2 SARS-COV-2 infection Severe infection severity severity of COVID-19 Smokers Spain Symptom the patient therapy treated Treatment World Health Organization [DOI] 10.1093/ibd/izaa221 PMC 바로가기 [Article Type] Observational Study
Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care MedicineSpecial Article Published on 2021-01-012022-10-29 Journal: Revista Brasileira de Terapia Intensiva [Category] COVID-19, SARS, [키워드] Admission African anticoagulation antivirals approach conducted Coronavirus infections country COVID-19 COVID-19/diagnosis COVID-19/therapy criteria Critically ill patient DelPhi diagnosis of SARS-CoV-2 East Evidence Evolution group had no Health Health Service immunomodulator Infection knowledge management Medicine methodology National pathology PICO Practice guidelines as topic professional Protective question recommendation recommendations Respiratory Support SARS-CoV-2 Support systematic review therapy Timor Treatment with COVID-19 [DOI] 10.5935/0103-507X.0103-507X-rbti-20210080 PMC 바로가기 [Article Type] Special Article
Biomodulina T (InmunyVital ® ) Restores T Cells and Helps Contain COVID-19Immunology Published on 2020-12-092022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] Biomodulina T COVID-19 immunomodulator immunosenescence Immunotherapy InmunyVital T cells vaccine enhancer [DOI] 10.3389/fimmu.2020.606447 PMC 바로가기 [Article Type] Immunology
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial심각하고 치명적인 COVID-19가 있는 성인의 피하 토실리주맙: 전향적 공개 표지 비통제 다기관 시험Clinical Trial Published on 2020-12-012022-09-12 Journal: International immunopharmacology [Category] MERS, SARS, 임상, 진단, [키워드] added all-cause mortality rate Antiviral approved body temperature changes in clinical parameter concerning coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patients Critical Critical disease dose early stage Endpoint enrolled immunomodulator immunomodulatory IMPROVE in both group interleukin interleukin 6 Laboratory male Most patient multicenter Multicenter trial occurred Open-label oral temperature oxygen saturation oxygen-support Oxygenation Patient patients died Potential reduce reported required Respiratory failure respiratory rate risk of death Serious Adverse Event Seven Severe patient severe patients Significant significantly standard care Subcutaneous subjects Therapeutic approach therapy Tocilizumab tocilizumab administration variable [DOI] 10.1016/j.intimp.2020.107102 PMC 바로가기 [Article Type] Clinical Trial
Hydroxychloroquine and COVID-19 – A narrative reviewReview Published on 2020-12-012023-07-12 Journal: The Indian journal of tuberculosis [Category] SARS, [키워드] COVID-19 Hydroxychloroquine immunomodulator pandemic QT prolongation [DOI] 10.1016/j.ijtb.2020.06.004 PMC 바로가기 [Article Type] Review
Is there any potential management against COVID-19? A systematic review and meta-analysisCOVID-19에 대한 잠재적인 관리가 있습니까? 체계적인 검토 및 메타 분석Meta-Analysis Published on 2020-12-012022-09-11 Journal: Daru : journal of Faculty of Pharmacy, Tehran Univ [Category] 치료제, [키워드] 95% CI 95% confidence interval Anakinra antiviral therapy article articles calculate Clinical effect Clinical improvement Clinical management convalescent plasma Convalescent plasma therapy COVID-19 COVID-19 infection COVID-19 pandemic Critical database declined Effect Efficacy eligibility criteria estimation Frequency had no Hydroxychloroquine ICU identify immunomodulator immunomodulators Immunomodulatory agent Immunomodulatory agents Improvements inception infected patients intensive care intensive care unit Intervention management mechanical ventilation medication medications Meta-analysis Mortality mortality rate Negative conversion no effect outcome outcomes Patient plasma plasma therapy Quantitative analysis random-effects model reduce Relative risk risk SARS-CoV-2 Scholar searched shown significantly standard treatment suggested systematic review therapy Tocilizumab Treatment was performed [DOI] 10.1007/s40199-020-00367-4 PMC 바로가기 [Article Type] Meta-Analysis
Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in SpainResearch Published on 2020-11-262022-11-01 Journal: Critical Care [Category] COVID-19, SARS, [키워드] C-reactive protein carried Characteristics children clinical collected Corticosteroid COVID-19 criteria Critical care Critically ill described diarrhea discharged distress dysfunction fatigue feature Fever Gastrointestinal symptom had no healthy Immunoglobulin immunomodulator Inflammatory intensive care unit invasive ventilation IQR Kawasaki disease Laboratory LDH less Lymphocyte count manifestation mechanical ventilation median MIS-C Most patient multicentre National neutrophil count Older Patient patients patients died pediatric Pediatric multisystem inflammatory syndrome temporally associated with COVID-19 Pneumonia presenting Prevalence procalcitonin proportion receive recruited Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR Shock Spain syndrome therapeutic Toxic shock syndrome treated vasoactive drug vomit with COVID-19 [DOI] 10.1186/s13054-020-03332-4 PMC 바로가기 [Article Type] Research
Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive catsReview Published on 2020-11-132022-10-28 Journal: The Veterinary Quarterly [Category] COVID-19, MERS, SARS, [키워드] Antiviral antiviral drugs antiviral therapy approach cat caused Clinical effect Clinical sign coronavirus current feline Feline infectious peritonitis Feline infectious peritonitis virus FIP GS-441524 immune response immune system immune-mediated disease immunomodulator immunosuppressive agent increased survival information pandemic patients pharmacological positive Protease inhibitor provide reduce resulting robust SARS-CoV-2 stimulate Therapeutics treat Treatment viral-induced virulent virus [DOI] 10.1080/01652176.2020.1845917 PMC 바로가기 [Article Type] Review